Bone Morphogenetic Protein 6 in Skeletal Metastases from Prostate Cancer
Author Information
Author(s): P Autzen, CN Robson, A Bjartell, AJ Malcolm, ML Johnson, DE Neal, FC Hamdy
Primary Institution: University of Newcastle upon Tyne
Hypothesis
This study examines the expression of BMP-6 mRNA in matched prostatic primary and secondary bony lesions and in isolated skeletal metastases from prostatic adenocarcinomas, as well as other common human malignancies.
Conclusion
BMP-6 mRNA is strongly expressed in the majority of skeletal metastases from prostatic adenocarcinomas, suggesting it may be a potential marker and mediator of skeletal metastases.
Supporting Evidence
- BMP-6 mRNA was detected in 11 out of 13 bone metastases from prostate carcinoma.
- BMP-6 was also expressed in three paired samples of primary prostate carcinoma and matching skeletal metastasis.
- Weak signals for BMP-6 were present in 5 out of 17 skeletal deposits from non-prostatic malignancies.
Takeaway
The study found that a protein called BMP-6 is often present in bone cancer from prostate tumors, which might help doctors understand and treat these cancers better.
Methodology
In situ hybridization was used to examine BMP-6 expression in matched primary and secondary prostatic adenocarcinomas and in isolated skeletal metastases.
Limitations
The study had a limited number of corresponding primary prostatic tumors.
Participant Demographics
Patients with established skeletal metastases from different primary cancers, including prostate, lung, kidney, breast, colon, and uterus.
Statistical Information
P-Value
0.0039
Statistical Significance
p=0.0039
Want to read the original?
Access the complete publication on the publisher's website